United States IVF Devices and Consumables Market Size, Share, Growth, and Industry Analysis, By Product Type (IVF Devices Incubators Micromanipulators Cryopreservation Equipment Imaging Systems (e.g., Time-Lapse Imaging) Others (IVF Workstations, Laser Systems) , IVF Consumables Culture Media Petri Dishes and Plates Catheters Syringes and Needles Disposable Gloves Other Consumables (Pipettes, Vials, Straws, etc.) ), By Application (Assisted Reproductive Technology (ART) , Fertility Clinics , Research and Academic Institutes , Hospitals and Surgical Centers ) and Forecast, 2026-2034

United States IVF Devices and Consumables Market Trends

Automation, Cryopreservation and Embryo Monitoring Reshape Laboratory Workflows

Laboratories are moving toward integrated incubation, imaging, micromanipulation and cryogenic workflows. CDC recorded 435,426 ART cycles in 2022, up 5.2% from 413,776 cycles in 2021; 184,423 of the 2022 cycles were egg or embryo banking cycles, representing roughly 42.4% of total cycles. Single-embryo transfers represented 85.9% of embryo transfers, reinforcing demand for precise laboratory handling and monitoring systems.

Adoption continues expanding. SART-member clinics reported 449,772 IVF treatment cycles for 2024, producing 97,549 cycles with a live birth and 100,158 IVF-born babies. This exceeded the 100,000-baby threshold for the first time. Meanwhile, approximately 500 U.S. clinics currently provide ART services, supporting recurring utilization of culture media, dishes, pipettes, vitrification products and other laboratory supplies.

United States IVF Devices and Consumables Market Drivers

Increasing IVF Procedure Volumes and Expanding Fertility-Care Utilization

Procedure expansion is a primary demand catalyst. ART cycles increased from 326,468 in 2020 to 413,776 in 2021 and 435,426 in 2022, while live-birth deliveries increased from 75,023 to 91,906 and 94,039, respectively. In 2022, ART-conceived infants represented approximately 2.6% of U.S. infants, with 98,289 live-born infants resulting from reported cycles. These volumes increase utilization of incubators, imaging equipment and high-frequency disposable laboratory products.

United States IVF Devices and Consumables Market Restraints

Complex Clinical Workflows, Treatment Economics and Outcome Variability

Despite increasing utilization, IVF remains clinically intensive. Of 435,426 ART cycles reported in 2022, 94,039 resulted in live-birth deliveries, while CDC reports a 37.5% live-birth-delivery rate for the relevant ART-cycle measure and an average ART patient age of 36.3 years. Outcomes also vary by patient age, diagnosis and procedure, creating economic and clinical barriers to repeated treatment cycles and equipment investment.

United States IVF Devices and Consumables Market Opportunities

Cryopreservation and High-Precision Laboratory Infrastructure Create Expansion Potential

Cryopreservation provides a substantial equipment and consumables opportunity. Banking cycles expanded from 123,304 in 2020 to 167,689 in 2021 and 184,423 in 2022, an increase of nearly 49.6% in two years. Banking consequently represented approximately 42.4% of 435,426 ART cycles during 2022. Growth in freezing, storage and subsequent frozen-embryo workflows supports demand for cryogenic equipment, vitrification media, straws, vials and controlled laboratory systems.

Challenges in United States IVF Devices and Consumables Market

Maintaining Laboratory Quality While Procedure Throughput Expands

Scaling laboratory throughput while preserving embryo-handling quality remains challenging. U.S. reporting clinics handled 435,426 ART cycles for 251,542 unique patients in 2022 across 457 clinics. These cycles generated 94,039 live-birth deliveries and 98,289 live-born infants. With 85.9% of embryo transfers being single-embryo transfers, laboratories require stringent process control, equipment reliability and precise consumable handling despite rising throughput.

United States IVF Devices and Consumables Market Segmentation

The market is segmented by product type, application, end use, technology and distribution channel. Product data indicate IVF devices represented approximately 65.1% of 2026 product revenue, while ART accounted for approximately 48.4% of the supplied 2026 application total.

By Product Type

IVF devices dominate, increasing from USD 692.77 million in 2025 to USD 814.07 million in 2026 and USD 2,959.80 million by 2034 at a 17.51% CAGR. The category includes incubators, micromanipulators, cryopreservation equipment, imaging systems, IVF workstations and laser systems.

IVF consumables rise from USD 373.03 million in 2025 to USD 436.78 million in 2026 and USD 1,543.20 million by 2034, recording a 17.09% CAGR. Culture media, dishes, catheters, syringes, needles, gloves, pipettes, vials and straws create recurring procurement requirements.

By Application

ART is the largest application, valued at USD 605.15 million in 2026 versus USD 516.91 million in 2025, and reaches USD 2,135.14 million by 2034 at a 17.07% CAGR. Fertility clinics account for USD 316.70 million in 2026 and carry a 17.17% CAGR.

Research and Academic Institutes are the fastest-growing application at a 17.66% CAGR, increasing from USD 195.75 million in 2026 to USD 719.01 million in 2034. Hospitals and Surgical Centers advance from USD 131.65 million to USD 471.84 million at a 17.30% CAGR.

By End Use

Fertility clinics constitute the principal end-use environment because IVF laboratories require integrated equipment and recurring disposable supplies for stimulation-to-transfer workflows. Hospitals provide an additional channel for procedure-linked fertility services and surgical interventions.

Research laboratories and diagnostic centers support specialized testing, embryology research and reproductive diagnostics. Their equipment requirements emphasize imaging, cryopreservation, controlled incubation and micromanipulation, while consumable utilization centers on sterile single-use products.

By Technology

Conventional IVF and ICSI form core laboratory technologies, with ICSI requiring precision micromanipulation systems and associated disposables. Cryopreservation techniques create additional demand for controlled freezing/storage equipment and vitrification consumables.

Time-lapse imaging technology supports continuous embryo observation without repeated removal from controlled incubation environments. Integration of imaging, incubation and digital workflow systems is increasing the technological intensity of modern embryology laboratories.

By Distribution Channel

Direct sales represent an important channel for sophisticated incubators, imaging platforms, micromanipulators and cryopreservation equipment because installation, validation, training and after-sales servicing influence procurement decisions.

Distributors and dealers broaden consumables availability, while online sales support standardized repeat purchases. High-frequency consumables are particularly suited to recurring procurement models, whereas capital systems generally retain more service-intensive sales processes.

United States IVF Devices and Consumables Market Counties Outlook

The United States accounts for 100% of the geographic scope assessed. Within the country, activity is concentrated in populous states and major fertility-care hubs. The supplied national total reaches USD 1,250.85 million in 2026 and USD 4,503.00 million in 2034.

California recorded 3.2% of infants as ART-conceived in 2022, versus 2.6% nationally; New York recorded 4.6%, New Jersey 5.6%, Massachusetts 6.2%, and the District of Columbia 7.3%. Nationally, 251,003 ART procedures intended for embryo transfer were reported, alongside 98,289 ART live-born infants, indicating substantial geographic variation in treatment penetration.

Top players in United States IVF Devices and Consumables Market

• CooperSurgical, Inc.
• Vitrolife AB
• FUJIFILM Irvine Scientific
• Thermo Fisher Scientific Inc.
• Cook Medical
• Hamilton Thorne
• Esco Medical
• Genea Biomedx
• Kitazato Corporation
• Nikon Corporation
• Olympus Corporation
• Eppendorf SE
• Corning Incorporated
• Merck KGaA
• Gynemed GmbH & Co. KG

Top Two Companies

• CooperSurgical:CooperSurgical holds a prominent competitive position through its broad fertility and reproductive-health portfolio spanning IVF laboratory equipment and consumable categories. Its positioning benefits from recurring laboratory demand for embryo-culture and handling products combined with capital-equipment requirements. The supplied dataset does not provide company-level percentage shares; therefore, no unsupported numerical company share is assigned. Competitive strength is instead associated with portfolio breadth, established fertility-clinic relationships and participation across multiple stages of the IVF laboratory workflow.
• Vitrolife:Vitrolife maintains a strong position in embryo-culture, time-lapse, laboratory and reproductive-genetics-related workflows. Its exposure to recurring consumables and technology-intensive IVF processes supports participation across both routine treatment and laboratory modernization. The mandatory dataset contains no verified company-level percentage share, so a numerical share cannot be stated without introducing unsupported data. Its competitive positioning centers on integrated embryology solutions, embryo assessment, culture environments and products used throughout assisted-reproduction workflows.

Recent Developments in the United States IVF Devices and Consumables Market

• 2026: SART reported that 449,772 IVF treatment cycles performed by member clinics in 2024 resulted in 100,158 IVF-born babies, surpassing 100,000 annual U.S. IVF births for the first time.
• 2025: Hamilton Thorne became part of Nexpring Health alongside Cook Reproductive Health, Planer, IVFtech, Gynemed, Gynétics, Microptic, TekEvent, and Embryotech, consolidating complementary fertility-care capabilities.
• 2025: CDC continued publishing clinic-specific ART success-rate resources covering U.S. reporting fertility clinics and differences by patient and procedure characteristics.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, historical context from 2022–2024 and forecasts through 2034. Mandatory supplied numerical tables serve as the primary basis for market valuation, product and application segmentation, CAGR and forecast calculations. Secondary validation uses CDC National ART Surveillance System and SART/ASRM statistics for procedure volumes, clinic activity, treatment penetration and recent industry developments. Percentages calculated from supplied tables are derived directly from stated values; no undisclosed segment or company revenue has been fabricated.